Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ValiRx PLC targets US institutions with new appointment

Burns McClellan has already carried out an institutional investor introductory project for ValiRx.
ValiRx PLC targets US institutions with new appointment
ValiRx wants more recognition in the US

ValiRx Plc (LON:VAL) has appointed a specialist investor relations firm to build its recognition among academic, clinical, and business leaders in the US. 

Burns McClellan has already carried out an institutional investor introductory project for ValiRx

Satu Vainikka, ValiRx’s chief executive, said its relationship with Burns McClellan was developing strongly and the company would benefit from enhanced engagement with US investors and other key partners in the US biotech sector.

ValiRx has one drug, VAL201 targeting prostate cancer, going through phase I/II trials, and has made an application to start a second for another cancer treatment, VAL401 that focuses on locally advanced or metastatic non-small cell lung cancer.

PhilW.jpg
Why Invest In ValiRx Plc? Read More Here

Register here to be notified of future VAL Company articles
View full VAL profile

ValiRx Plc Timeline

Big Picture
December 02 2016
Newswire
October 13 2016

Related Articles

shutterstock_327930536.jpg
December 02 2016
Life sciences firm ValiRx is poised for a busy year ahead as it progresses its lead drugs...
Drugs
February 06 2017
The hybrid pharma services and drug development group has hit some key milestones over this year as trial results are eyed.
1-SG02055.jpg
March 22 2016
e-Therapeutics is now targeting partners to accelerate the development of its drug discovery engine and commercialise compounds.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.